1Y Close · As of Aug 26, 2026
KWANGDONG PHARMACEUTICAL operates in the Pharmaceuticals sector.
Legal name: KWANGDONG PHARMACEUTICAL CO.,LTD
In fiscal year 2025, KWANGDONG PHARMACEUTICAL (009290) reported revenue of 1.66 trillion KRW, up 1.1% from 1.64 trillion KRW a year earlier.
Operating profit was 31.0 billion KRW and net income was 21.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 314.7 billion KRW, with a P/B of 0.44.
These figures can be verified in the DART filing (receipt no. 20260318001573).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 1.7T | 31.0B | 21.3B |
| 2024 | 1.6T | 30.1B | 41.8B |
| 2023 | 1.5T | 42.1B | 39.4B |
Recent Filings
Semi-Annual Report (2026.06)
Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
Earnings Preview (Informational Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 disposal(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-12 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |
| 2026-07-31 | Earnings Preview (Informational Disclosure) |